Figure 4
Figure 4. Reexposure of AML cells adjusted to 6% O2 result in a very rapid loss of surface and total CXCR4. (A) Live imaging (40×/1.5 NA) of OCI-AML3 cells at 6% (left) and 5 minutes reoxygenation with 21% O2 (right) show the loss of bound FITC-labeled CXCR4 antibody. (B) Similar results are found for U937 cells. (C) Flow cytometric analysis of OCI-AML3, either surface-stained or fixed with 2% PFA and methanol permeabilized for total CXCR4, shows a simultaneous loss of surface CXCR4 (left, ○) and total protein (right, ▴) within 5 minutes. Graphs show means and SD. (D) Treatment of OCI-AML3 with proteasome inhibitor lactacystin (10 mM) before reoxygenation prevents neither loss of surface expression of CXCR4 by flow cytometry nor total CXCR4 by Western blotting.

Reexposure of AML cells adjusted to 6% O2 result in a very rapid loss of surface and total CXCR4. (A) Live imaging (40×/1.5 NA) of OCI-AML3 cells at 6% (left) and 5 minutes reoxygenation with 21% O2 (right) show the loss of bound FITC-labeled CXCR4 antibody. (B) Similar results are found for U937 cells. (C) Flow cytometric analysis of OCI-AML3, either surface-stained or fixed with 2% PFA and methanol permeabilized for total CXCR4, shows a simultaneous loss of surface CXCR4 (left, ○) and total protein (right, ▴) within 5 minutes. Graphs show means and SD. (D) Treatment of OCI-AML3 with proteasome inhibitor lactacystin (10 mM) before reoxygenation prevents neither loss of surface expression of CXCR4 by flow cytometry nor total CXCR4 by Western blotting.

Close Modal

or Create an Account

Close Modal
Close Modal